Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biotene Moisturizing Mouth Spray is an over-the-counter oral care product designed as a saliva substitute to provide symptomatic relief for xerostomia (dry mouth). It contains a combination of enzymes, including glucose oxidase, lactoperoxidase, and lysozyme, which are intended to mimic the natural protective and moisturizing properties of human saliva. The University of Southern California (USC) initiated a Phase 4 clinical trial (NCT02522936) to evaluate the product's efficacy in reducing the discontinuation of oxybutynin, an anticholinergic medication for overactive bladder, by mitigating medication-induced dry mouth. However, the study was ultimately withdrawn. Biotene is classified as a topical oral moisturizer rather than a traditional small molecule pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biotene Moisturizing Mouth Spray.